Previous 10 | Next 10 |
LAKE FOREST, Ill., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that its executive team will host one-on-one inve...
LAKE FOREST, Ill., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it is raising its outlook for 2022 full-year...
Summary Assertio announced Q322 earnings last week. The company reported adjusted earnings per share of $0.85 for the 9m of 2022 and raised revenues guidance to >$141m. Management appears to have done a solid job putting Assertio's troubled past behind it although litigatio...
Assertio Holdings, Inc. (ASRT) Q3 2022 Earnings Conference Call November 8, 2022 16:30 ET Company Participants Matthew Kreps - Darrow Associates, Investor Relations Daniel Peisert - President & Chief Executive Officer Paul Schwichtenberg - Senior Vice Preside...
Assertio Therapeutics press release ( NASDAQ: ASRT ): Q3 Non-GAAP EPS of $0.22 beats by $0.11 . Revenue of $34.21M (+34.3% Y/Y) beats by $2.86M . The company increased its outlook for the full year 2022 to now anticipate net product sales greater than $141M, an...
Net Product Sales Increase 32% Year-Over-Year, Non-GAAP Adjusted EBITDA Increases 36% Increases Guidance for Net Product Sales and Adjusted EBITDA Debt Refinancing Extends Maturity, Reduces Cost and Increases Strategic Flexibility Expects Sympazan to Add $1...
Summary After a rough September, we’re approaching the season historically known for stronger performance. Although small-cap stocks can be more volatile than large-caps, cheap stocks often have high return potential. Offering attractive valuations, above-average growth, an...
We’re quickly approaching the end of the first month in Q4. With that has come ten months of wild trading activity and plenty of volatility. Heading into November, there are plenty of new catalysts to account for, including next week’s FOMC meeting. But before November begins,...
LAKE FOREST, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release third quarter 2022 fin...
Summary This year's bear markets have resulted in a fall in portfolio performance. Healthcare, the second best sector this year, is defensive and has stood the test of time. The Fed’s stance and volatile price swings that include declines of more than 20% in the major index...
News, Short Squeeze, Breakout and More Instantly...
Assertio Therapeutics Inc. Company Name:
ASRT Stock Symbol:
NASDAQ Market:
Assertio Therapeutics Inc. Website:
LAKE FOREST, Ill., July 24, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will rel...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ASRT on July 3, 2024 06:04AM ET. ASRT was trading at $1.15 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...
LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief...